All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Why could mass spectrometry substitute IFE in diagnosis and monitoring of MM?

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub spoke to Bruno Paiva, University of Navarra, Pamplona, ES. We asked, Why could mass spectrometry substitute immunofixation electrophoresis (IFE) in diagnosis and monitoring of MM?

Why could mass spectrometry substitute IFE in diagnosis and monitoring of MM?

Paiva describes the benefits of mass spectrometry over IFE, including improved sensitivity, specificity, and prevention of monoclonal antibody interference. He then analyzes the potential for synergy across different imaging techniques when predicting and measuring patient outcomes.

 

Share:
More about...